Management of advanced adult soft tissue sarcoma

Sarcoma

Volumn 7, Issue 2, 2003, Pages 43-55

  Bramwell, Vivien H C ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTHRACYCLINE DERIVATIVE; BIRICODAR; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; IMATINIB; TRABECTEDIN; TROGLITAZONE;

CANCER LOCALIZATION; CANCER RECURRENCE; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; HUMAN; LYMPH NODE METASTASIS; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; NOMENCLATURE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA;

EID: 0042887650     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577140310001607266     Document Type: Review

References (123)

1. Ballo MT, Zagars GK, Pollack A, Pisters WT, Pollock RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy or combined surgery and radiation therapy. J Clin Oncol 1999; 17: 158-67.
2. International Union Against Cancer. TNM Classification of Malignant Tumors. 5th edn. Sobin LH, Wittekind Ch, eds. 1997. New York: John Wiley.
3. Zahm SH, Tucker MA, Fraumeni JF. Soft tissue sarcomas. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. 1996; 984-99.
4. Lawrence W, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas: a pattern of care survey of the American College of Surgeons. Ann Surg 1987; 205: 349-59.
5. Pollock RE, Karnell LH, Menck HR, Winchester DP. The National Cancer Database report on soft tissue sarcoma. Cancer 1996; 78: 2247-57.
6. Pisters PWT, Leung DHY, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14: 1679-89.
7. Coindre J-M, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchère D, Sastre X, Vilain M-O, Bonichon F, Bui BN. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. Cancer 2001; 91: 1914-26.
8. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: Recent advances in understanding of their biology. Hum Pathol 1999; 30: 1213-20.
9. Chan JK. Mesenchymal tumors of the gastrointestinal tract: A paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cells of Cajal in the pathogenesis of gastrointestinal diseases. Am J Pathol 1998; 152: 1259-69.
10. Kindbloom LG, Remotti HE, Aldenberg F, Meiss-Kindbloom JM. Gastrointestinal pacemaker cell tumor (GIPACT) gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Adv Anat Pathol 1999; 6: 19-40.
11. Somerhausen NDSA, Fletcher CDM. Gastrointestinal stromal tumours: an update. Sarcoma 1998; 2: 133-41.
12. Ng E-H, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992; 69: 1334-41.
13. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
14. Fong Y, Goit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults: analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993; 217: 72-7.
15. Weingrad DN, Rosenberg SA. Early lymphatic spread of osteogenic and soft tissue sarcomas. Surgery 1978; 84: 231-40.
16. Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 1987; 60: 1800-8.
17. Billingsley KG, Lewis JJ, Leung DHY, Casper ES, Woodruff JM, Brennan MF. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 1999; 85: 389-95.
18. Frost DB. Pulmonary metastasectomy for soft tissue sarcomas: Is it justified? J Surg Oncol 1995; 59: 110-5.
19. Harrison LE, Brennan MF, Newman E, Former JG, Picardo A, Blumgart LH, Fong Y. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 1997; 121: 625-32.
20. Karakousis CP, Blumenson LE, Canavese G, Rao U. Surgery for disseminated abdominal sarcoma. Am J Surg 1992; 163: 560-4.
21. Espana P, Chang P, Wiernik PH. Increased incidence of brain metastases in sarcoma patients. Cancer 1980; 45: 377-80.
22. Bindal RK, Sawaya RE, Leavens ME, Taylor SH, Guinee VF. Sarcoma metastatic to the brain: Results of surgical treatment. Neurosurgery 1994; 35: 185-91.
23. Slater JD, McNeese MD, Peters LP. Radiation therapy for unresectable soft tissue sarcomas. Int J Rad Oncol Biol Phys 1986; 12: 1729-34.
24. Nori D, Shupak K, Shiu MH, Brennan MF. Role of brachytherapy in recurrent extemity sarcoma in patients treated with prior surgery and irradiation. Int J Radiat Oncol Biol Phys 1991; 20: 1229-33.
25. Stannard CE, Vernimmen FJ, Jones DTL, Van Wijk AL, Brennan SM, Visser AM, et al. The neutron therapy clinical programme at the National Accelerator Centre (NAC). Bull Cancer/Radiotherapy 1996; 83: 87-92s.
26. Chauvel P. Osteosarcomas and adult soft tissue sarcomas: is there a place for high LET radiation therapy? Ann Oncol 1992; 3: S107-10.
27. Gunderson LL, Nagorney DM, McIlrath DC, Fieck JM, Wieand HS, Martinez A, et al. External beam and intraoperative electron irradiation for locally advanced soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1993; 25: 647-56.
28. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: implications for decision making in the clinic. Hematol Oncol Clin N Am 1995; 9: 765-85.
29. Keohan ML, Taub RN. Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Sem Oncol 1997; 24: 572-9.
30. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5: 1191-8.
31. Keizer HJ, Crowther D, Nielsen OS, Van Oosterom AT, Muguiro HJ, Van Pottelberghe C, et al. EORTC group phase II study of oral etoposide for pretreated soft tissue sarcoma. Sarcoma 1997; 1: 99-101.
32. Crawley CR, Judson IR, Verrill M, Hill C, Raynaud FI. A phase I/II study of a 72-h continuous infusion of etoposide in advanced soft tissue sarcoma. Sarcoma 1997; 1: 149-54.
33. Edmonson JH, Buckner JC, Long HJ, Loprinzi CL, Schaid DJ. Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas. J Natl Cancer Inst 1989; 81: 863-6.
34. Saeter G, Alvegard TA, Monge OR, Strander H, Turesson I, Klepp R, et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group phase II study. Eur J Cancer 1997; 33: 1551-8.
35. Bramwell VHC, Anderson D, Charette M. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma - a meta-analysis and clinical practice guideline. Sarcoma 2000; 4: 103-12.
36. Edmonson JH, Ryan LM, Blum RH, Brooks JSJ, Shiraki M, Frytak S, Parkinson DR. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-75.
37. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-45.
38. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, et al. An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-85.
39. Verma S, Bramwell V. Dose-intensive chemotherapy in advanced adult soft tissue sarcoma. Expert Rev Anticancer Ther 2002; 2: 7201-15.
40. Lopez M, Vici P, Di Lauro L, Conti F, Paoletti G, Ferraironi A, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998; 16: 86-92.
41. Seymour L, Bramwell V, Moran LA, et al. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prev Control 1999; 3: 145-59.
42. Judson I, Radford J, Harris M, Blay J-Y, van Hoesel Q, le Cesne A, et al. Randomized phase II trial of liposomal doxorubicin (Doxil/Caelyxl) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcomas - a study by the EORTC Soft Tissue and Bone Sarcoma Group trial. Eur J Cancer 1999; 37: 870-7.
43. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-8.
44. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-84.
45. Buesa JM, Lopez-Pousa A, Martin J, Anton A, del Muro JG, Bellmunt J, et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998; 9: 871-6.
46. Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, et al. Effect of high dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000; 36: 61-7.
47. s an outpatient study in sarcomas. Proc Am Soc Clin Oncol 1998; 17: 511.
48. Tichler T, Ghodsizade E, Brenner H. Failure of continuous infusion high dose ifosfamide as second line treatment for sarcomas: poor response rate and unacceptable renal and C.N.S. toxicity. Proc Am Soc Clin Oncol 1999; 18: 544.
49. van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Judson I, Krzemienlecki K, Svancarova L, et al. Results of randomized phase II studies of the EORTC SoftTissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002; 18: 2397-406.
50. Lorigan PC, Verweij J, Papai Z, Rodenhuis S, le Cesne A, Leahy M, et al. Randomised phase III trial of two investigational schedules of ifosfamide versus standard dose doxorubicin in patients with advanced or metastatic soft tissue sarcoma (ASTS). Proc Am Soc Clin Oncol 2002; 21: 405a.
51. Frustaci S, Comandone A, Bearz A, Boglione A, Buonadonna A, Stefanovski P, et al. Efficacy and tolerability of an ifosfamide continuous infusion (IFO-C.I.) soft tissue sarcoma (STS) patients (pts). Proc Am Soc Clin Oncol 1998; 17: 518.
52. Frustaci S, Buonadonna A, Galligioni E, Favaro D, De Paoli A, Lo Re G, et al. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A pilot study. J Clin Oncol 1997; 15: 1418-26.
53. Leyvraz S, Bacchi M, Cerny T, Lissoni A, Sessa C, Bressoud A, et al. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Ann Oncol 1998; 9: 877-84.
54. Frustaci S, Buonadonna A, Romanini A, Comandone A, Dalla Palma M, Gamucci T, et al. Increasing doses of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian Group on Rare Tumors. Tumori 1999; 85: 229-33.
55. De Pas T, Curigliano G, Masci G, Catania C, Comandone A, Boni C, et al. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin in adult patients with advanced soft tissue sarcomas. Ann Oncol 2002; 13: 161-6.
56. Hicks LG, Balcerzak SP, Zalupski M. GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study. Cancer Invest 1996; 14: 507-12.
57. Vadhan-Raj S, Patel S, Burgess M, Papadopoulos N, Plager C, Johnston T, et al. Phase II trial of adriamycin (A), ifosfamide (I), mesna (M) uroprotection, dacarbazine (D) (MAID) with PIXY321 (GM-CSF/IL-3 fusion protein) or G-CSF in patients (pts) with soft tissue sarcoma (STS). Proc Am Soc Clin Oncol 1996; 15: 525.
58. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopoulos NE, Jenkins J, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcoma. Am J Clin Oncol 1998; 21: 317-21.
59. Pronzato P, Losardo P, Pensa F. High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study. Cancer Chemo Pharmacol 1998; 41: 513-6.
60. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16: 1438-43.
61. De Pas T, De Braud F, Orlando L, Nole F, Munzone E, Zampino MG, et al. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Ann Oncol 1998; 9: 917-9.
62. Palumbo R, Neumaier C, Cosso M, Bertero G, Raffo P, Spadini N, et al. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer 1999; 35: 66-72.
63. Lopez-Pousa A, Buesa JM, Montalar J, Martin J, Maurel J, del Muro JG, et al. Phase II trial of doxorubicin and high-dose ifosfamide (DXHDI) in advanced previously untreated soft tissue sarcoma (TS) patients. A study of the Spanish Group for Research on Sarcomas (GEIS). Proc Am Soc Clin Oncol 1999; 18: 544.
64. Serrone L, Zeuli M, Gamucci T, Nardi M, Cognetti F. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Cancer Chemother Pharmacol 2001; 47: 206-10.
65. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18: 2676-84.
66. Bui NB, Demaille MC, Chevreau C, Blay JY, Cupissol D, Rios M, et al. qMAID vs MAID + 25% with G-CSF in adults with advanced soft tissue sarcomas (ST). First results of a randomized study of the FNCLCC Sarcoma Group. Proc Am Soc Clin Oncol 1998; 17: 517.
67. Reichardt P, Verweij J, Crowther D. Current controversies in cancer: should high-dose chemotherapy by used in the treatment of soft tissue sarcoma? Eur J Cancer 1997; 33: 1351-60.
68. Pinkerton CR. Megatherapy for soft tissue sarcomas. EBMT experience. Bone Marrow Transplant 1991; 7: 120-2.
69. Dumontet C, Biron P, Bouffet E, Blay J-Y, Meckenstock R, Chauvin F, et al. High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transplant 1992; 10: 405-8.
70. Kessinger A, Petersen K, Bishop M, Schmit-Pokorny K. High dose therapy (HDT) with autologous hematopoietic stem cell rescue (HSCR) for patients with metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 1994; 13: 480.
71. Blay J-Y, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18: 3643-50.
72. Bokemeyer C, Franzke A, Hartmann JT, Schober C, Arseniev L, Metzner B, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221-7.
73. Reichardt P, Tilgner J, Mapara MY, Hohenberger P, Dorken B. Dose-intensive chemotherapy with stem cell support for adult patients with advanced soft tissue sarcoma: a phase I study. Sarcoma 1997; 1: 219.
74. Myong H, Rosen G, Forscher C, Hurvitz C, Hamburg S, Qasabian L, et al. High dose chemotherapy (CTX) with autologous peripheral stem cell transplantation (PSCT) for advanced sarcoma. Proc Am Soc Clin Oncol 1998; 17: 511.
75. Chow W, Somlo G, Doroshow JH, Reardon D, ter Veer A, Leong L, et al. Sequential high-dose chemotherapy (HDCT) and peripheral blood progenitor cell rescue (PBPC) in young adults with soft tissue and bone sarcomas (SARC). Proc Am Soc Clin Oncol 1998; 17: 512.
76. Falk MH, Salat C, Ochmann O, Knabe H, Mempel W, Sauer HJ, et al. High-dose chemotherapy (HDCT) with peripheral blood stem cell rescue (PBSCR) for adults with soft tissue sarcomas (STS). Proc Am Soc Clin Oncol 1999; 18: 544.
77. Samuels BL, Gale DM, Michel J, Murray JL, Das Gupta TK, Lad T, et al. Dose dense chemotherapy for sarcomas using whole-blood derived peripheral stem cell rescue. Proc Am Soc Clin Oncol 1999; 18: 543.
78. Montemurro F, Grosso F, Ferrante P, Rosti G, Aglietta M. High-dose chemotherapy with hematopoietic stem cell transplant (HDCT/HSCT) for soft tissue sarcoma (STS) of the adult: Analysis of the European Group for Blood and Marrow Transplantation (EBMT) Registry. Proc Am Soc Clin Oncol 2001; 20: 363a.
79. Falk MH, Hiddemann W, Kolb HJ, Mempel W, Ochmann O, Ostermann H, Salat C, et al. High-dose chemotherapy with peripheral blood stem cell rescue as consolidation treatment for adult patients with chemosensitive metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 2001; 20: 361a.
80. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. New Engl J Med 2000; 13: 1069-76.
81. Lotz JP, Cure H, Janvier M, Morvan F, Asselain B, Guillemot M, et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cell transplantation (HSCT) for metastatic breast cancer (MBC): results of the French Protocol PEGASE 04. Proc Am Soc Clin Oncol 1999; 18: 43.
82. Tuveson DA, Fletcher JA. Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol 2001; 13: 249-55.
83. Heymach JV. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol 2001; 13: 261-9.
84. Maki TG. Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol 2001; 13: 270-4.
85. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96: 3951-6.
86. Goss G, Demetri G. Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. Surg Oncol 2000; 9: 53-9.
87. Demetri GD, Spiegelman B, Fletcher CD, Mueller E, Sarraf P, Naujoks R, et al. Differentiation of liposarcomas in patients treated with the PPARγ ligand troglitazone: documentation of biologic activity in myxoid/round cell and pleomorphic subtypes. Proc Am Soc Clin Oncol 1999; 18: 535.
88. Presant CA, Bartolucci AA, Lowenbraun S. Effects of amphotericin B on combination chemotherapy of metastatic sarcomas. Cancer 1984; 53: 214-8.
89. van der Graaf WTA, Dijk AC, Sleijfer DTh, Hoekstra HJ, de Vries EGE, Willemse PHB, et al. Epirubicin, vindesine and ifosfamide (EVI) plus or minus amiodarone in the treatment of soft tissue sarcomas. Proc Am Soc Clin Oncol 1996; 15: 525.
90. Bramwell VHC, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, et al. Safety and efficacy of the MDR inhibitor Biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8: 383-93.
91. Colvin OM. Drug resistance in the treatment of sarcomas. Semin Oncol 1997; 24: 580-91.
92. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16: 2986-99.
93. Demetri GD. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 2002; 13 (Suppl 1): S7-9.
94. Le Cesne A, Blay J, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, et al. ET-743 is an active drug in adult soft-tissue sarcoma (STS): a STBSG-EORTC phase II trial. Proc Am Soc Clin Oncol 2001; 20: 353a.
95. Brain EG. Safety and efficacy of ET-743: the French experience. Anticancer Drugs 2002; 13: S22-4.
96. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors (GIST), a phase I study. Lancet 2001; 358: 1421-3.
97. Demetri GD, van Mehren M, Blanke CD, Van der Abbeele, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 2002; 347: 472-80.
98. Benjamin R, Rankin C, Fletcher C, Von Mehren M, Blanke C, Maki R, et al. Effectiveness of Imatinib mesylate for metastatic GIST at two dose levels: Phase III Early Results of Sarcoma Intergroup Study S0033. Proc Am Soc Clin Oncol 2003; 22: 814.
99. Mitchell G, Thomas JM, Harmer CL. Aggressive fibromatosis: evidence for a stable phase. Sarcoma 1998; 2: 149-54.
100. Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer 1989; 64: 1192-4.
101. Azzarelli A, Casali P, Fissi S, Gronchi A, Rasponi A, Bertulli R. Effective control of advanced aggressive fibromatosis with chemotherapy. Eight years of experience with methotrexate + vinblastine in 27 patients. Sarcoma 1997; 1: 200.
102. Reich S, Overberg-Schmidt US, Buhrer C, Henze G. Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors. J Clin Oncol 1999; 17: 1086-90.
103. Seiter K, Kemeny N. Successful treatment of a desmoid tumor with doxorubicin. Cancer 1993; 71: 2242-4.
104. Hamilton L, Blackstein M, Berk T, McLeod RS, Gallinger S, Madlensky L, Cohen Z. Chemotherapy for desmoid tumors in association with familial adenomatous polyposis: a report of three cases. Can J Surg 1996; 39: 247-52.
105. Mace J, Biermann JS, Sondak V, McGinn C, Hayes C, Thomas D, Baker L. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95: 2373-9.
106. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD. Molecular targeting of platelet-derived growth factor b by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002; 20: 3586-91.
107. Casali P, Pastorino U, Bertulli R, Azzarelli A, Quagliuolo V, Fissi S, et al. Complete surgery of lung metastases combined with chemotherapy in 31 adult soft tissue sarcomas: long-term results. Sarcoma 1997; 1: 196.
108. Hohenberger P, Reichardt P, Tilgner J, Kettelhack C, Schlag PM. Results of combined surgery and high-dose chemotherapy + G-CSF for metastatic or locally advanced soft tissue sarcoma. Proc Am Soc Clin Oncol 1999; 18: 542.
109. Wiklund T, Saeter G, Strander H, Alvegard T, Blomqvist C. The outcome of advanced soft tissue sarcoma patients with complete tumor regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience. Eur J Cancer 1997; 33: 357-61.
110. Putnam JB, Madden T, Tran HT, Benjamin RS. Isolated single lung perfusion (ISLP) with adriamycin for unresectable sarcomatous metastases. Proc Am Soc Clin Oncol 1997; 16: 500.
111. Mavligit GM, Zukwiski AA, Ellis LM, Chuang VP, Wallace S. Gastrointestinal leiomyosarcoma metastatic to the liver. Cancer 1995; 75: 2083-8.
112. Bonvalot S, Lecesne A, Terrier P, Le Pechoux C, Elias D, Lasser PH. Preliminary evaluation of complete resection of major sarcomatosis followed by randomization of early post-operative intraperitoneal chemotherapy. Sarcoma 1997; 1: 202.
113. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999; 6: 645-50.
114. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer SoftTissue and Bone Sarcoma Group study. J Clin Oncol 1999; 17: 150-7.
115. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506-11.
116. Blay J-Y, van Glabbeke M, Verweij J, van Oosterom AT, Le Cesne A, Oosterhuis JW, et al. Advanced soft tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39: 64-9.
117. Reichardt P, Van Glabbeke M, Mouridsen HT, Verweij J, Radford JA, Rodenhuis S, Azzarelli A, et al. Recurrent disease is an independent factor associated with inferior survival in patients with advanced soft tissue sarcomas. A retrospective analysis of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). Proc Am Soc Clin Oncol 2001; 20: 354a.
118. Esnaola NF, Rubin B, Baldini E, Vasudevan N, Demetri GD, Fletcher CD, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg 2001; 234: 215-23.
119. Jameson M, Harvey V, Thompson P, Evans B, Childs J. Juvenile-type tumors in adults carry a grim prognosis. Proc Am Soc Clin Oncol 1998; 17: 521.
120. Benjamin RS. Grade 3 nausea, vomiting and myelosuppression or progressive, metastatic sarcoma? J Clin Oncol 1987; 5: 833-5.
121. Canellos GP. Myelosuppression and 'conventional' chemotherapy: what price, what benefit? J Clin Oncol 1993; 11: 1-2.
122. Edmonson JH. Needed: qualitative improvement in antisarcoma therapy. J Clin Oncol 1995; 13: 1531-3.
123. Benjamin RS, Rouesse J, Bourgeois H, van Hoesel QGCM. Current controversies in cancer: Should patients with advanced sarcomas be treated with chemotherapy? Eur J Cancer 1998; 34: 958-65.